Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celgene Corp (CELG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,933,516
  • Shares Outstanding, K 699,250
  • Annual Sales, $ 13,003 M
  • Annual Income, $ 2,940 M
  • 36-Month Beta 1.53
  • Price/Sales 3.74
  • Price/Cash Flow 9.14
  • Price/Book 10.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 2.08
  • Number of Estimates 2
  • High Estimate 2.14
  • Low Estimate 2.02
  • Prior Year 1.87
  • Growth Rate Est. (year over year) +11.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.91 +1.06%
on 11/15/18
84.59 -17.67%
on 10/17/18
-14.64 (-17.37%)
since 10/16/18
3-Month
68.91 +1.06%
on 11/15/18
95.30 -26.93%
on 08/31/18
-20.51 (-22.75%)
since 08/16/18
52-Week
68.91 +1.06%
on 11/15/18
110.81 -37.15%
on 12/11/17
-33.71 (-32.62%)
since 11/16/17

Most Recent Stories

More News
Celgene (CELG) Gains But Lags Market: What You Should Know

Celgene (CELG) closed at $69.98 in the latest trading session, marking a +0.5% move from the prior day.

CELG : 68.97 (-1.44%)
Lyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis

Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry and investors to support user-driven innovation, announced it is joining forces with Celgene (NASDAQ:...

CELG : 68.97 (-1.44%)
CELGZ : 0.93 (-1.06%)
Celgene Corp Has Returned 19.9% Since SmarTrend Recommendation (CELG)

SmarTrend identified a Downtrend for Celgene Corp (NASDAQ:CELG) on September 11th, 2018 at $87.66. In approximately 2 months, Celgene Corp has returned 19.87% as of today's recent price of $70.24.

CELG : 68.97 (-1.44%)
Insperity Inc is Among the Companies in the Human Resource & Employment Services Industry With the Highest P/E Ratio (NSP, WAGE, ASGN, HSII, RHI)

Below are the three companies in the Human Resource & Employment Services industry with the highest price to earnings (P/E) ratios. P/E is an important valuation tool when comparing companies in the same...

CELG : 68.97 (-1.44%)
Celgene Corp Falls 3.24% on Heavy Volume: Watch For Potential Rebound

Celgene Corp (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $71.62 to a high of $74.00. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $73.45...

CELG : 68.97 (-1.44%)
Prothena (PRTA) Reports Narrower-Than-Expected Loss in Q3

Prothena (PRTA) posts narrower-than-expected loss in the third quarter. With the failure of lead drug, NEOD001, the focus is now on its mid-stage candidate, prasinezumab.

CELG : 68.97 (-1.44%)
PRTA : 11.39 (+0.26%)
GILD : 68.94 (-1.20%)
RHHBY : 31.2700 (+0.84%)
Celgene (CELG) Outpaces Stock Market Gains: What You Should Know

Celgene (CELG) closed the most recent trading day at $75.09, moving +1.1% from the previous trading session.

CELG : 68.97 (-1.44%)
Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates

Corcept (CORT) reports in-line earnings in the third quarter of 2018 and reaffirms its revenue guidance for 2018.

CORT : 12.76 (-1.92%)
CELG : 68.97 (-1.44%)
PFE : 43.47 (+0.60%)
BMY : 53.76 (+0.92%)
Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock

Agios' (AGIO) loss tops estimates in Q3. Its precision medicine Tibsovo's performance in the very first quarter after approval in July leads to a significant year-over-year revenue growth.

AGIO : 68.90 (+2.42%)
CELG : 68.97 (-1.44%)
CLBS : 4.89 (-1.21%)
GILD : 68.94 (-1.20%)
bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat

bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.

CELG : 68.97 (-1.44%)
BLUE : 121.79 (-0.81%)
GILD : 68.94 (-1.20%)
REGN : 341.71 (+0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CELG with:

Business Summary

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID,...

See More

Key Turning Points

2nd Resistance Point 71.05
1st Resistance Point 70.52
Last Price 68.97
1st Support Level 69.18
2nd Support Level 68.37

See More

52-Week High 110.81
Fibonacci 61.8% 94.80
Fibonacci 50% 89.86
Fibonacci 38.2% 84.92
Last Price 68.97
52-Week Low 68.91

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar